PFE enters July with a notable reversal in the short-selling story — bears have pulled back sharply over the past week, yet the stock has continued sliding, closing at $24.08 after an 8% drop over the past month.
The most interesting development this week is the disconnect between short covering and price weakness. Short interest has fallen 17% in seven days to 2.9% of the free float — roughly 165 million shares — unwinding much of the build reported in last week's note, which had seen positioning climb to 3.5% of float around 200 million shares. The short score has eased in lockstep, dropping from a recent peak of 40.3 on June 22 to 36.7 now. That reversal is genuine: shorts are reducing exposure, not adding. Yet the stock still fell 2.6% on the week, which suggests selling pressure is coming from elsewhere — likely long-side liquidation rather than fresh bearish conviction. Borrow conditions reinforce this read. Availability has actually loosened dramatically, expanding to 3,511% from around 2,584% a week ago — meaning the lending pool is far from strained. Cost to borrow remains negligible at 0.48%, up only modestly from 0.36% last week. There is no mechanical squeeze in the making. Options traders are equally subdued — the put/call ratio at 0.87 barely registers against its 20-day average of 0.86, producing a z-score close to zero. No unusual hedging demand is visible.
The Street's posture is cautious but not bearish outright, with the bulk of recent analyst activity clustered in the neutral-to-hold band. Most major houses — Morgan Stanley, BofA, UBS, Citigroup — have maintained neutral-equivalent ratings while making modest target adjustments around the $26–$28 range, broadly in line with the mean consensus target near $29. That target implies roughly 21% upside from current levels, a gap that has widened as the stock has drifted lower. RBC Capital made the most directional move in the recent window, upgrading from Underperform to Sector Perform on June 10, though the $25 target sits below the current price, making it a qualified re-rating at best. Guggenheim and HSBC remain the outliers with Buy ratings and targets well above $30, but their last moves were in March, before the stock's most recent leg lower. On valuation, the P/E has compressed to 8.3x — down from higher levels a month ago — while the EV/EBITDA has drifted lower to 7.7x. The forward EPS momentum score ranks in only the 33rd percentile on a 30-day basis, though the 12-month forward EPS increase ranks in the 97th percentile, reflecting an unusually favorable base-effect comparison. The dividend score ranks in the 94th percentile, a signal that yield-focused buyers remain a natural floor for the stock.
Insider activity offers little conviction in either direction. The only trade within the past 90 days was a small $51,400 sale by the Chief Accounting Officer in early June — routine in size and significance. The broader cluster of executive sells in late February, including CEO Albert Bourla's $12.6 million disposal near $27, looks more notable in hindsight given where the stock has since traded. None of the top institutional holders in the latest Q1 filings flagged a material directional move. JP Morgan Asset Management remains the largest named holder with 7.6 million shares, and added modestly in the quarter.
Pfizer's most closely correlated peer BMY rose 3.8% on the week while PFE fell 2.6% — a divergence that underscores the stock-specific nature of Pfizer's current weakness rather than a sector-wide rotation. GSK also edged higher over the same period.
Q2 earnings land on July 28. The last two prints produced modest first-day moves — a 0.9% gain after May's report and a 2% drop after the April release — so the market has not been pricing in dramatic surprises around Pfizer's numbers recently. With short sellers having just retreated and long-side sellers still active, the question heading into the July 28 print is less about whether bears are building a position and more about what it would take to re-engage the buyer base that has been absent for most of the past month.
See the live data behind this article on ORTEX.
Open PFE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
